Suppr超能文献

同步性乳腺癌:MRI上的表型相似性

Synchronous Breast Cancer: Phenotypic Similarities on MRI.

作者信息

Wang Hui, van der Velden Bas H M, Chan Hui Shan M, Loo Claudette E, Viergever Max A, Gilhuijs Kenneth G A

机构信息

Image Sciences Institute, University Medical Center Utrecht, Utrecht, Netherlands.

Department of Radiology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

出版信息

J Magn Reson Imaging. 2020 Jun;51(6):1858-1867. doi: 10.1002/jmri.27026. Epub 2019 Dec 19.

Abstract

BACKGROUND

Previous studies have shown discrepancies between index and synchronous breast cancer in histology and molecular phenotype. It is yet unknown whether this observation also applies to the MRI phenotype.

PURPOSE

To investigate whether the appearance of breast cancer on MRI (i.e. phenotype) is different from that of additional breast cancer (i.e. synchronous cancer), and whether such a difference, if it exists, is associated with prognosis.

STUDY TYPE

Retrospective.

POPULATION

In all, 464 consecutive patients with early-stage ER+/HER2- breast cancer were included; 34/464 (7.3%) had 44 synchronous cancers in total (34 ipsilateral, 10 contralateral).

SEQUENCE

1.5T, contrast-enhanced T -weighted.

ASSESSMENT

We assessed imaging phenotype using 50 quantitative features from each cancer and applied principal component analysis (PCA) to identify independent properties. The degree of phenotype difference was assessed. An association between phenotype differences and prognosis in terms of the Nottingham Prognostic Index (NPI) and PREDICT score were analyzed.

STATISTICAL TESTS

PCA; Wilcoxon rank sum test; Benjamini-Hochberg to control the false discovery rate.

RESULTS

PCA identified eight components in patients with ipsilateral synchronous cancer. Six out of eight were significantly different between index and synchronous cancer. These components represented features describing texture (three components, P < 0.001, P < 0.001, P = 0.004), size (P < 0.001), smoothness (P < 0.001), and kinetics (P = 0.004). Phenotype differences in terms of the six components were split in tertiles. Larger phenotype differences in size, kinetics, and texture were associated with significantly worse prognosis in terms of NPI (P = 0.019, P = 0.045, P = 0.014), but not for the PREDICT score (P = 0.109, P = 0.479, P = 0.109). PCA identified six components in patients with contralateral synchronous cancer. None were significantly different from the index cancer (P = 0.178, P = 0.178, P = 0.178, P = 0.326, P = 0.739, P = 0.423).

DATA CONCLUSION

The MRI phenotype of ER+/HER2- breast cancer was different from that of ipsilateral synchronous cancer and a large phenotype difference was associated with worse prognosis. No significant difference was found for synchronous contralateral cancer.

LEVEL OF EVIDENCE

3 Technical Efficacy: Stage 4 J. Magn. Reson. Imaging 2020;51:1858-1867.

摘要

背景

先前的研究表明,原发性乳腺癌与同期乳腺癌在组织学和分子表型上存在差异。目前尚不清楚这一观察结果是否也适用于MRI表型。

目的

研究乳腺癌在MRI上的表现(即表型)是否与其他乳腺癌(即同期癌)不同,以及这种差异(如果存在)是否与预后相关。

研究类型

回顾性研究。

研究对象

总共纳入了464例连续的早期ER+/HER2-乳腺癌患者;其中34/464(7.3%)共患有44例同期癌(34例同侧,10例对侧)。

序列

1.5T,对比增强T加权成像。

评估

我们使用来自每个癌症的50个定量特征评估成像表型,并应用主成分分析(PCA)来识别独立特征。评估表型差异程度。分析表型差异与诺丁汉预后指数(NPI)和预测评分所反映的预后之间的关联。

统计检验

PCA;Wilcoxon秩和检验;Benjamini-Hochberg方法控制错误发现率。

结果

PCA在同侧同期癌患者中识别出八个成分。其中八个中的六个在原发性癌和同期癌之间存在显著差异。这些成分代表了描述纹理(三个成分,P < 0.001,P < 0.001,P = 0.004)、大小(P < 0.001)、平滑度(P < 0.001)和动力学(P = 0.004)的特征。六个成分方面的表型差异分为三分位数。在大小、动力学和纹理方面较大的表型差异与NPI所反映的预后显著较差相关(P = 0.019,P = 0.045,P = 0.014),但与预测评分无关(P = 0.109,P = 0.479,P = 0.109)。PCA在对侧同期癌患者中识别出六个成分。没有一个与原发性癌有显著差异(P = 0.178,P = 0.178,P = 0.178,P = 0.326,P = 0.739,P = 0.423)。

数据结论

ER+/HER2-乳腺癌的MRI表型与同侧同期癌不同,较大的表型差异与较差的预后相关。对侧同期癌未发现显著差异。

证据水平

3 技术效能:4级 J.Magn.Reson.Imaging 2020;51:1858 - 1867。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ae2/7318126/3f39d9d0cfd7/JMRI-51-1858-g001.jpg

相似文献

1
Synchronous Breast Cancer: Phenotypic Similarities on MRI.
J Magn Reson Imaging. 2020 Jun;51(6):1858-1867. doi: 10.1002/jmri.27026. Epub 2019 Dec 19.
2
Identifying relations between imaging phenotypes and molecular subtypes of breast cancer: Model discovery and external validation.
J Magn Reson Imaging. 2017 Oct;46(4):1017-1027. doi: 10.1002/jmri.25661. Epub 2017 Feb 8.
5
Comparison between an abbreviated and full MRI protocol for detecting additional disease when doing breast cancer staging.
J Magn Reson Imaging. 2019 Jun;49(7):e222-e230. doi: 10.1002/jmri.26339. Epub 2018 Oct 22.

本文引用的文献

1
Evaluation of Biomarkers in Multiple Ipsilateral Synchronous Invasive Breast Carcinomas.
Arch Pathol Lab Med. 2019 Feb;143(2):190-196. doi: 10.5858/arpa.2017-0494-OA. Epub 2018 Sep 7.
4
Breast MRI radiogenomics: Current status and research implications.
J Magn Reson Imaging. 2016 Jun;43(6):1269-78. doi: 10.1002/jmri.25116. Epub 2015 Dec 10.
5
Radiomics: Images Are More than Pictures, They Are Data.
Radiology. 2016 Feb;278(2):563-77. doi: 10.1148/radiol.2015151169. Epub 2015 Nov 18.
6
Radiogenomics: what it is and why it is important.
J Am Coll Radiol. 2015 Aug;12(8):862-6. doi: 10.1016/j.jacr.2015.04.019.
7
Uncovering the genomic heterogeneity of multifocal breast cancer.
J Pathol. 2015 Aug;236(4):457-66. doi: 10.1002/path.4540. Epub 2015 May 7.
9
Fully automated deformable registration of breast DCE-MRI and PET/CT.
Phys Med Biol. 2013 Feb 21;58(4):1221-33. doi: 10.1088/0031-9155/58/4/1221. Epub 2013 Feb 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验